Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 4

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 4
---
UTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS                                   |   6 |
| RISK FACTORS                                                                           |   8 |
| THE PRIVATE PLACEMENT                                                                  |  36 |
| USE OF PROCEEDS                                                                        |  38 |
| DILUTION                                                                               |  39 |
| SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT                         |  40 |
| SELLING STOCKHOLDERS                                                                   |  41 |
| MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY                                  |  43 |
| MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS |  44 |
| BUSINESS                                                                               |  51 |
| MANAGEMENT                                                                             |  68 |
| EXECUTIVE AND DIRECTOR COMPENSATION                                                    |  71 |
| CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS                                   |  76 |
| DESCRIPTION OF OUR SECURITIES                                                          |  79 |
| PLAN OF DISTRIBUTION                                                                   |  83 |
| EXPERTS                                                                                |  84 |
| LEGAL MATTERS                                                                          |  84 |
| WHERE YOU CAN FIND ADDITIONAL INFORMATION                                              |  84 |
| INDEX TO FINANCIAL STATEMENTS                                                          | F-1 |

The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the Common Stock offered under this prospectus. The registration statement, including the exhibits, can be read on our website and the website of the Securities and Exchange Commission. See “Where You Can Find Additional Information.”

Information contained in, and that can be accessed
through our web site, www.bioaffinity.com, shall not be deemed to be part of this prospectus or incorporated herein by reference
and should not be relied upon by any prospective investors for the purposes of determining whether to purchase the Common Stock offered
hereunder.

Unless the context otherwise requires, the terms ““we,”
“us,” “our,” “the Company,” “bioAffinity” and “our business” refer to bioAffinity
Technologies, Inc. and “this offering” refers to the offering contemplated in this prospectus.

<div align='center'>i

ABOUT THIS PROSPECTUS</div>

Neither we nor the Selling Stockholders have authorized
anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective
amendment, or any applicable prospectus supplement